Biodexa (BDRX) CFO details multi-year stock option grants

Rhea-AI Filing Summary

Biodexa Pharmaceuticals Plc filed an initial insider report listing stock option holdings for Chief Financial Officer Fiona Mary Powell. The filing shows three option grants: one over 286 American Depositary Shares with a $327.5000 exercise price expiring on February 10, 2034, and two over ordinary shares covering 7,500 and 8,750 shares with exercise prices of $5.4000 and $7.4100, expiring on June 16, 2030 and July 14, 2031 respectively. Footnotes explain vesting schedules, note that some shares are already fully vested and exercisable, and clarify that each American Depositary Share represents 100,000 ordinary shares.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Powell Fiona Mary

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 286 shares (Direct)

Footnotes (1)

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer. The shares underlying this option are 100% vested and can be exercised immediately. The exercise price for this option is denominated in British pounds sterling at a price of GBP 259.324 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2629. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise. The exercise price for this option is denominated in British pounds sterling at a price of GBP 4.04 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise. The exercise price for this option is denominated in British pounds sterling at a price of GBP 5.55 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Powell Fiona Mary

(Last) (First) (Middle)

C/O BIODEXA PHARMACEUTICALS PLC

1 CASPIAN POINT, CASPIAN WAY

(Street)

CARDIFF CF104DQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Biodexa Pharmaceuticals Plc [ BDRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	02/10/2034	American Depositary Shares(2)	286	$327.5(4)	D
Stock Option (right to buy)	(3)	06/16/2030	Ordinary Shares	7,500	$5.4(5)	D
Stock Option (right to buy)	(3)	07/14/2031	Ordinary Shares	8,750	$7.41(6)	D

Explanation of Responses:

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

3. The shares underlying this option are 100% vested and can be exercised immediately.

4. The exercise price for this option is denominated in British pounds sterling at a price of GBP 259.324 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2629. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

5. The exercise price for this option is denominated in British pounds sterling at a price of GBP 4.04 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

6. The exercise price for this option is denominated in British pounds sterling at a price of GBP 5.55 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney

	/s/ Fiona Mary Powell	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Biodexa (BDRX) disclose in Fiona Powell’s Form 3 filing?

The Form 3 filing lists Chief Financial Officer Fiona Mary Powell’s existing stock option holdings. It details three option grants over American Depositary Shares and ordinary shares, including exercise prices, share counts, and expiration dates, without reporting any new purchases or sales.

How many shares are covered by Fiona Powell’s stock options at Biodexa (BDRX)?

The filing shows options over 286 American Depositary Shares and two ordinary-share grants covering 7,500 and 8,750 shares. These totals reflect her reported derivative positions, giving investors a view of her potential equity exposure through options.

What are the exercise prices and expirations of the Biodexa (BDRX) options held by Fiona Powell?

The American Depositary Share option has a $327.5000 exercise price and expires on February 10, 2034. The ordinary-share options have exercise prices of $5.4000 and $7.4100, expiring on June 16, 2030 and July 14, 2031, respectively.

How do Biodexa (BDRX) American Depositary Shares relate to ordinary shares?

The filing explains that each American Depositary Share represents 100,000 ordinary shares. This ratio helps investors understand the scale of the 286 American Depositary Shares covered by one of Fiona Powell’s stock option grants relative to the company’s ordinary share count.

What vesting information is provided for Fiona Powell’s Biodexa (BDRX) stock options?

Footnotes state that some option shares vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter, while other option shares are already 100% vested and immediately exercisable, subject to her continued service where applicable.

Does Fiona Powell’s Form 3 for Biodexa (BDRX) show any insider buying or selling?

The data categorize all three entries as holdings with unknown transaction codes and show zero buy or sell transactions. This indicates the Form 3 functions as an initial statement of existing option positions rather than reporting new market trades.